Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate. | Disc Medicine is laying off a fifth of its workforce as the ...
Disc Medicine is laying off about 20% of its workforce after the Food and Drug Administration denied its application for accelerated approval of its bitopertin treatment.
Preview this article 1 min The latest round of layoffs at Catalent is yet another blow to Baltimore's struggling pharmaceutical industry. Drug manufacturing giant to cut 77 local jobs in new round of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results